CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination.

Autor: Ravindranath AK; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kaur S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Wernyj RP; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kumaran MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Miletti-Gonzalez KE; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Present address: Delaware State University, Dover, DE, USA., Chan R; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lim E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Madura K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA., Rodriguez-Rodriguez L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Obstetrics and Gynecology, New Brunswick, Rutgers Cancer Institute of New Jersey, NJ, USA.

Publikováno v: Oncotarget [Oncotarget] 2015 Sep 22; Vol. 6 (28), pp. 26308-21.

Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells.

Autor: Muthukumaran N; Division of Gynecologic Oncology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Room 2009, 195 Little Albany Street, New Brunswick, 08901, USA., Miletti-González KE, Ravindranath AK, Rodríguez-Rodríguez L

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2006 Aug; Vol. 4 (8), pp. 511-20.